A Multicenter, Randomized, Double Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy M16 067

At a Glance

IRB#IRB18-0942

Lead PhysicianDavid T. Rubin

Collaborator(s)N/A

EligibilityRecruiting